FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
STAMFORD, Conn., Oct. 26, 2016 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for the third quarter ended September 30, 2016 on November 2, 2016 before the NASDAQ market open.
The company will not be conducting a conference call in conjunction with this earnings release.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
[email protected]
Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
[email protected]
Media:
Dan Budwick
Pure Communications, Inc.
973-271-6085
[email protected]
